Take a look at the recommended changes needed to address what ANH-USA says are unethical, burden-shifting tactics used by FTC regarding health product advertising.

Xlear says the move calls FTC’s authority to require clinical studies for non-pharmaceutical health products into question.

The brief requests the dismissal of FTC’s complaint against Xlear based on the Supreme Court’s recent decision in Loper Bright Enterprises v. Raimondo. 

The Loper Bright decision has terminated the Chevron doctrine, reining in anti-democratic and unlawful extensions of government.